Here’s what we’re looking out for this week in the worlds of pharma and biotech:

Still waiting on that fantastic FDA pick

This may yet be the week that President Trump unveils the new FDA commissioner. If you trust the pollsters, former FDA deputy commissioner Dr. Scott Gottlieb is emerging as the biopharma community’s top choice. Whoever Trump’s so-called fantastic pick is, we can bet that he or she will veer in the direction of deregulation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy